Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment
Portfolio Pulse from Vandana Singh
Protagonist Therapeutics Inc (PTGX) announced positive results from the Phase 2b FRONTIER 1 trial of JNJ-2113, a psoriasis treatment developed by Janssen Biotech, a unit of Johnson & Johnson (JNJ). The drug hit its primary and secondary endpoints, showing significant improvements in skin lesions. However, it fell short of rival treatment Skyrizi, commercialized by AbbVie Inc (ABBV), in terms of PASI 90 score. PTGX shares are up 3.41% premarket.
July 05, 2023 | 11:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ABBV's Skyrizi outperformed JNJ-2113 in terms of PASI 90 score, which could boost investor confidence in ABBV and drive the stock price up.
The fact that ABBV's Skyrizi outperformed JNJ-2113 in terms of PASI 90 score could boost investor confidence in ABBV and drive the stock price up as it indicates a competitive advantage in the market.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 70
POSITIVE IMPACT
Positive trial results for JNJ-2113, developed by JNJ's unit Janssen Biotech, could boost JNJ's stock, but competition from ABBV's Skyrizi may limit gains.
The positive trial results for JNJ-2113, developed by JNJ's unit Janssen Biotech, could boost investor confidence in JNJ and drive the stock price up. However, the fact that JNJ-2113 fell short of ABBV's Skyrizi in terms of PASI 90 score could limit the potential gains as it indicates stronger competition in the market.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Positive trial results for JNJ-2113 could boost investor confidence in PTGX, but falling short of a rival treatment may limit gains.
The positive trial results for JNJ-2113 are a significant milestone for PTGX, which could boost investor confidence and drive the stock price up. However, the fact that JNJ-2113 fell short of ABBV's Skyrizi in terms of PASI 90 score could limit the potential gains as it indicates stronger competition in the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100